Approval of First Oral GLP-1 for Weight Loss in UK

MedPal AI is selling hype, not results—no financials, just big promises and partnerships.

Risk flags

• ●Operational risk is high because MedPal AI has not disclosed any data on patient uptake, prescription volumes, or revenue from its New Health clinic. Without evidence of actual demand, the business model remains unproven.
• ●Financial disclosure risk is acute: the announcement omits all core financial metrics, including revenue, profit, cash flow, and operating expenses. This lack of transparency makes it impossible to assess the company’s financial health or runway.
• ●Execution risk is significant, as the company must rapidly convert regulatory news into paying customers in a private-pay market. If uptake is slower than anticipated, the window of opportunity could close before meaningful revenue is generated.
• ●Forward-looking risk is substantial: the majority of the company’s claims are projections or beliefs about future demand, not realised outcomes. Investors are being asked to buy into a story, not a track record.
• ●Market access risk is present because the drug is not yet available on the NHS and remains under NICE review. The current addressable market is limited to private payers, which may be much smaller than implied.
• ●Pattern risk exists in the company’s reliance on external data (Novo Nordisk’s US launch) as a proxy for its own prospects. There is no evidence that US prescription trends will map directly to the UK private market or to MedPal AI’s offering.
• ●Capital intensity risk is flagged by the mention of a 24/7 AI-powered automated pharmacy and robotic dispensing technology. These are expensive to build and operate, and without scale, could become a financial drag.
• ●Key person risk is moderate: while Jason Drummond is named as CEO, there is no evidence of external institutional backing or notable third-party validation. The absence of such support increases the risk that the company is over-reliant on internal optimism.

Bottom line

For investors, this announcement is a classic example of a company leveraging a major regulatory event to generate excitement, but without providing any direct evidence of commercial traction or financial performance. The narrative is credible only insofar as the regulatory approval is real and the US market has shown strong demand for oral semaglutide, but there is no proof that MedPal AI is positioned to capture similar demand in the UK. The partnership with Epassi is potentially valuable, but without data on actual user engagement or conversion, it remains a theoretical asset. The absence of any financial disclosure—no revenue, no patient numbers, no operational milestones—means investors are being asked to take management’s word on faith. If MedPal AI wants to be taken seriously by sophisticated investors, it must disclose concrete metrics: patient sign-ups, prescription volumes, revenue, and cost structure. The next reporting period should be scrutinized for evidence of real uptake and financial progress; if these are not forthcoming, the investment case weakens considerably. At this stage, the announcement is a weak signal—worth monitoring, but not acting on—unless and until hard data is provided. The single most important takeaway is that MedPal AI’s story is all potential and no proof; until that changes, caution is warranted.

Announcement summary

(AIM: MPAL) MedPal AI plc announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted UK marketing authorisation for the first oral GLP-1 receptor agonist tablet (oral semaglutide) for weight loss and weight management. The approval, granted to Novo Nordisk, makes the tablet available on a prescription-only basis to adults who are obese (BMI of 30 or above) or overweight (BMI of 27 to 30). According to Novo Nordisk's announcement of 7 June 2026, US prescriptions for the tablet surpassed three million in just over five months, equivalent to approximately one prescription filled every five seconds. More than 80% of new pill prescriptions were for patients new to GLP-1 therapy. The approval is directly relevant to MedPal AI's private GLP-1 weight management clinic, New Health (new.co.uk), which is launching nationally. The tablet is not currently available on the NHS and remains subject to evaluation by the National Institute for Health and Care Excellence (NICE), meaning private provision is presently the only route to access. MedPal AI has a partnership agreement with Epassi UK Limited, granting exclusive, zero-cost access to the MedPal AI app across Epassi's network of 11M+ employees at major firms.

Disagree with this article?